PDPN and neoplasm: Several interactions result in the tight binding of platelets to tumor cells, including (i) the binding of C-type lectin-like receptor 2 (CLEC-2) on platelets with podoplanin on tumor cells and (ii) the binding between p-selectin on platelets and Sialyl–Lewisx-conjugates on tumor cells, and (iii) integrin αIIbβ3 on platelets and αVβ3 on tumor cells, both of which bind to fibrin [72].